anesthesia and semaglutide Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists ASA Advises No Longer Holding

d MannWhitney U-test

org/10.1016/s0009-2797(97)00146-4

Several possible explanations for changes in urinary frequency include: Improved glycaemic control : As Ozempic helps lower blood glucose levels, patients with previously poorly controlled diabetes may notice reduced urination compared to their baseline, as high blood sugar itself causes increased urination (polyuria) Dietary changes : Some patients alter their fluid intake or dietary habits when starting Ozempic, particularly as the medication often reduces appetite Weight loss : Weight reduction, which commonly occurs with Ozempic treatment for type 2 diabetes, may influence fluid balance Other common causes of increased urination unrelated to Ozempic include: Urinary tract infections Enlarged prostate in men Caffeine or alcohol consumption Other medications, particularly diuretics Anxiety It's important to note that Ozempic is licensed in the UK for the treatment of type 2 diabetes, while Wegovy (also semaglutide) is the licensed product for weight management

For injectable formulations, proper injection technique and site rotation can minimize injection site reactions

Women who have been on GLP-1 medications should ensure adequate thyroid monitoring during this transition period

Good technique makes the process nearly painless and maximizes medication delivery